Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MUSIC: Macitentan in Idiopathic Pulmonary Fibrosis
NCT00903331Phase 2Completed
- Sponsor
- Actelion Pharmaceuticals Ltd
- Start
- May 2009
- Primary completion
- Jun 2011
- Modality
- Small Molecules
- Countries
- 12
01
Overview
Phase 2, randomised, double-blind trial in idiopathic pulmonary fibrosis (IPF) comparing Macitentan 10 mg with Placebo (2 arms). Primary endpoint: Forced Vital Capacity at 12 months. Started May 2009; status: completed.
02
Drugs
macitentan
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on NCT00903331.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00903331.